908 Devices appoints co-founder Christopher Brown to board of directors

BOSTON - 908 Devices Inc. (NASDAQ:MASS), a company specializing in handheld devices for chemical analysis, announced Monday the appointment of Christopher D. Brown, PhD, to its Board of Directors, effective immediately.

Brown, a co-founder of 908 Devices, currently serves as Vice President of Analytics R&D at Repligen Corporation (NASDAQ:RGEN). He previously held the positions of Chief Technology Officer & Vice President of Research & Development at 908 Devices from February 2012 to March 2023, and later served as Chief Product Officer until March 2025 when Repligen acquired the company’s bioprocessing portfolio.

Before his tenure at 908 Devices, Brown worked as a platform architect at Apple Inc. (NASDAQ:AAPL) focusing on future health technologies. Apple, currently valued at $2.93 trillion, maintains its position as a prominent player in the Technology Hardware industry according to InvestingPro analysis. Want deeper insights into Apple’s market position and growth potential? InvestingPro offers comprehensive research reports with expert analysis on Apple and 1,400+ other top stocks, transforming complex data into actionable intelligence. His prior experience includes roles as Senior Director at Thermo Fisher Scientific Inc. (NYSE:TMO) and leading product development at Ahura Scientific before its acquisition by Thermo Fisher. During his time at Apple, he contributed to a company that InvestingPro data shows has maintained strong financial health with an overall score of "GOOD" and has consistently raised its dividend for 13 consecutive years.

Brown holds a bachelor’s degree in mathematics and chemistry from Brandon University and a PhD in chemistry from Dalhousie University, specializing in statistical and machine learning methods for chemical data.

"Chris played a pivotal role in shaping our product strategy and assembling the exceptional team that continues to advance our technology today," said Kevin J. Knopp, CEO and Co-founder of 908 Devices.

Kevin Hrusovsky, Chairman of 908 Devices, added, "His deep expertise in advanced analytical technologies and long-standing commitment to innovation will be a valuable asset to the Board and to the company."

908 Devices develops handheld devices for chemical analysis used in health and safety applications, including detection of illicit drugs, toxic carcinogens, and security threats.

This information is based on a press release statement from the company.

In other recent news, Apple’s iPhone sales surged 15% year-on-year during April and May, marking its strongest performance for this period since the COVID-19 pandemic, according to Counterpoint Research. The company achieved the number one position in China’s smartphone market in May, with significant growth also seen in the United States, Japan, India, and Middle Eastern markets. In a strategic move, Foxconn, a major Apple supplier, significantly increased its iPhone exports from India to the United States, with exports reaching $3.2 billion between March and May. This shift is seen as part of Apple’s strategy to navigate US tariffs on Chinese products. Additionally, Apple has set a spring 2026 target for a delayed upgrade to its Siri voice assistant, aiming to enhance its artificial intelligence offerings. The upgrade is expected to be part of the iOS 26.4 software update. Meanwhile, CLSA analysts initiated coverage on Shin Zu Shing with a High-Conviction Outperform rating, anticipating the company’s transition to manufacturing hinges for Apple’s first foldable iPhone, projected to launch in the second half of 2026. This strategic shift is expected to significantly contribute to Shin Zu Shing’s revenue and earnings growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.